Table 3.
BAFF gene expression and future activity: percentage of visits with future disease activity over the next year by BAFF gene expression
| Variable | 1st Tertial (%, n=91) | 2nd Tertial (%, n=92) | 3rd Tertial (%, n=92) | p Value | Adjusted p value for age, ethnicity and sex |
|---|---|---|---|---|---|
| PGA >1 | 12 | 12 | 29 | 0.0033 | 0.039 |
| SELENA-SLEDAI ≥2 | 35 | 52 | 70 | <0.0001 | <0.0001 |
| Urine protein:creatinine ratio ≥0.5 | 4 | 6 | 18 | 0.0034 | 0.049 |
| Anti-dsDNA ≥10 (Crithidia) | 9 | 16 | 35 | <0.0001 | 0.0005 |
| C3 <79 | 6 | 7 | 22 | 0.0011 | 0.0056 |
| C4 <79 | 4 | 8 | 18 | 0.0035 | 0.0033 |
| ESR >20 | 37 | 47 | 68 | <0.0001 | 0.0003 |
BAFF, B cell activating factor; PGA, physician global assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SELENA, Safety of Estrogens in Lupus Erythematosus: National Assessment.